Myeloid Leukemia

Drug induces morphologic, molecular, and clinical remissions in myelofibrosis

By

Imetelstat, a novel telomerase-inhibiting drug, has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis, according to a new study. The results were presented at the 2013 ASH Annual Meeting, in New Orleans.

Possible new acute leukemia marker treatment target identified

By

MicroRNA-155 has been identified as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia whose chromosomes look normal under the microscope.

Withdrawn leukemia drug has good results in UK study

Gemtuzumab ozogamicin, discontinued here in 2010, reduced relapse risk and improved survival in Welsh patients with acute myeloid leukemia.

Only a few gene mutations important in leukemia

Most of the hundreds of mutations found in acute myeloid leukemia (AML) genomes occur randomly as part of the aging process, unrelated to cancer.

HIV drug can prevent complications after stem-cell transplant

An HIV drug helped lower the risk of graft-versus-host disease in persons with blood cancer who had stem-cell transplants to rebuild bone marrow.

Medical Treatments for Chronic Myelogenous Leukemia

Medical Treatments for Chronic Myelogenous Leukemia

This fact sheet educates patients about the causes of and treatment options for CML.

Managing Practical Concerns Raised by CML

Managing Practical Concerns Raised by CML

The following fact sheet educates patients with chronic myelogenous leukemia about getting help sorting through treatment options, managing side effects, and finding financial assistance.

Wayward gene found, vanquished in some East Asians with CML and NSCLC

Researchers found that a gene mutation prevents tyrosine kinase inhibitors from working in some East Asian cancer patients, and can correct this.

Genetic profile IDs leukemia patients for high-dose chemotherapy

Persons with acute myeloid leukemia who harbor specific gene mutations may have improved overall survival with higher doses of chemotherapy.

Addition of gemtuzumab ozogamicin ups survival in AML

Addition of gemtuzumab ozogamicin ups survival in AML

Phase 3 trial shows improved event-free, overall survival versus standard therapy alone.

Genetic predictors of AML outcome get more specific

Advanced profiling of gene mutations in acute myeloid leukemia could potentially be used to help predict prognosis and guide treatment decisions.

Specific Mutations in AML Affect Response to Therapy

Specific Mutations in AML Affect Response to Therapy

Also, bone marrow cells in myelodysplastic syndromes, secondary AML are clonal.

Ten-Year CML Survival Estimate of 68 Percent With Imatinib

Ten-Year CML Survival Estimate of 68 Percent With Imatinib

Good long-term survival for chronic myeloid leukemia after failed interferon alpha treatment.

Gleevec wins wider approval for use in GI cancer

By

Gleevec (imatinib mesylate) has been granted regular approval by the FDA for use in adults following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST).

High rate of leukemia in elderly may be due to stem cell aging

Hematopoietic stem cells from healthy persons older than 65 years make fewer immunoprotective lymphocytes than do stem cells from healthy persons aged 20 to 35 years.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs